These results imply FGFR4 targeted therapy to ameliorate cardiovascular disease could be safely used in CKD without obvious adverse effects on mineral metabolism, unlike the effects of anti-FGF23 antibodies20. This evidence concerns the gene FGF23 and cardiovascular disorder.